Skip to main content




Tokyo, September 21, 2017 --- Hitachi, Ltd. Healthcare Business Unit (“Hitachi”) today announced that it has developed a compact particle therapy system to address the growing demand for particle therapy among a broad range of hospitals. The system offers a single treatment room equipped with a 360 degree fully rotating gantry (“1G”).

Compared to previous systems developed by Hitachi, the new 1G system has a smaller footprint, lower installation costs and shorter installation times. Equipped with Hitachi's advanced Spot Scanning irradiation, an irradiation method with a proven track record at leading hospitals across the world, the 1G system also comes with Hitachi's cone beam CT system as standard equipment, enabling precise patient positioning.

Hitachi has been supplying world-class facilities around the world with its cutting edge proton therapy systems and intends to address the needs of even more medical institutions with its compact 1G system.

The 1G system will be introduced at the American Society for Oncology Society (ASTRO) Annual Meeting to be held in San Diego from September 24, 2017.

About Particle Therapy

Particle therapy is a type of radiation treatment used to treat cancer in which protons from a hydrogen atom are extracted and accelerated up to 70% the speed of light. Its energy is concentrated directly on the tumor while avoiding radiation dose to the surrounding healthy tissues. The acceleration of hydrogen atoms is used in what is called proton therapy, while the acceleration of carbon ions is used in heavy ion particle therapy. Patients experience no pain during treatment and the procedure has very few side effects compared with that of traditional radiotherapy. In most cases, patients can continue with their normal daily activities while undergoing treatment, thus maintaining their Quality of Life. For these reasons, it continues to gain attention as a cutting-edge form of cancer therapy.

Overview of Spot-Scanning Irradiation Technology

Spot-scanning irradiation technology does not scatter proton beams as with conventional proton beam therapy. Rather, it repeatedly turns a narrow proton beam on and off at high speed as it progressively changes location to irradiate entire tumor volumes. Protons can be aimed with high precision according to the targeted tumors, even those with complex shapes, while minimizing the impact on nearby healthy tissue. Furthermore, customized equipment such as collimators and boluses are not required.

Cone Beam CT (CBCT)

To further improve the accuracy of PBT, there is a constant need for accurate imaging of the internal structure of the tumor region. Information on the location of bone is obtained from traditional orthogonal x-rays and the motion of tumors is captured by RGPT. These are then combined with the ability to identify healthy tissue surrounding a tumor, particularly the location and shape of soft tissue via CBCT, allowing for greater therapeutic dose to be directed at the tumor while significantly reducing the risk of irradiating healthy tissue. The rotating gantry mounted CBCT system provides these three-dimensional anatomical images of patients, at isocenter immediately prior to being treated, dramatically increasing the precision of the treatments.

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society's challenges. The company's consolidated revenues for fiscal 2016 (ended March 31, 2017) totaled 9,162.2 billion yen ($81.8 billion). The Hitachi Group is a global leader in the Social Innovation Business, and it has approximately 304,000 employees worldwide. Through collaborative creation, Hitachi is providing solutions to customers in a broad range of sectors, including Power / Energy, Industry / Distribution / Water, Urban Development, and Finance / Government & Public / Healthcare. For more information on Hitachi, please visit the company's website at

This website includes information intended for healthcare professionals.
Please note that all descriptions in this website conform to the Pharmaceutical and Medical Device Act in Japan as well as other laws and regulations in Japan. Model names, specifications and configurations of products in overseas market outside Japan may be different by the countries.